Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 November 2023 | Story Anthony Mthembu | Photo SUPPLIED
Prof Frans Prinsloo
Prof Frans Prinsloo, the newly appointed Vice-Dean: Learning, Teaching, Innovation and Digitalisation in the Faculty of Economic and Management Sciences at the UFS.

The Faculty of Economic and Management Sciences (EMS) at the University of the Free State (UFS) has appointed Prof Frans Prinsloo as the Vice-Dean: Learning, Teaching, Innovation, and Digitalisation. Prof Prinsloo officially started his new role on 1 November 2023. “I am excited at the prospect of being able to support the academics in the faculty, enabling them to develop successful graduates who will not only sustain themselves and their families, but who can also function in and contribute positively to a dynamic world being transformed by technology,” Prof Prinsloo indicated. 

What the new role entails

According to Prof Prinsloo, the role includes overseeing and providing strategic leadership regarding the teaching and learning portfolio within the faculty. The portfolio he is responsible for looks at teaching and learning policies as well as the development of new curricula in the faculty, among others. In addition, as part of his work, he indicated that, “I will also have to ensure that the faculty’s teaching approaches remain relevant and responsive to our diverse body of students’ learning needs to ensure their academic success, but also to develop essential graduate attributes.  A further focus will be that the curricula of our academic programmes position our graduates to be in demand by employers and enable them to contribute meaningfully to the economy and society.”

Furthermore, Prof Prinsloo is responsible for ensuring that the academic programmes within the faculty are of high quality and accredited by all relevant top industry bodies.

The future of the faculty 

As an Auditing academic for more than 25 years and Director of the UFS School of Accountancy for the past five years, Prof Prinsloo plans to use the experience he has acquired, as well as the leadership positions he has held throughout his career, to lead the faculty to new heights. “I look forward to positioning the UFS Faculty of Economic and Management Sciences as a faculty with effective and cutting-edge teaching approaches to ensure our students’ academic success, and to have quality and unique academic programmes that draw top students from across South Africa, Africa, and beyond – in line with the UFS Vision 130,” he said. 

In addition, part of what he aims to accomplish in his term as Vice-Dean is working to establish the faculty and its academics as recognised thought leaders and innovators as far as teaching and learning is concerned. Prof Prinsloo also highlighted that, “We also need to ensure that the successes attained by the faculty and its staff are shared within and outside of the UFS, and as such, I will also be responsible for strategically leading the marketing efforts of the faculty.” 

However, his efforts to advance the faculty are not only focused on the progress of the staff and their offerings, but also on that of the students. In fact, he indicated that, “I would also like to use this position to explore ways of further supporting our students, particularly recognising the multitude of challenges such as ineffective study skills, financial and mental wellness-related challenges that many of our students face.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept